WHO15/102人活化凝血因子X国际标准品FXa

世界卫生组织激活凝血因子X(FXa)参考试剂(15/102)由世界卫生组织生物标准化专家委员会于2017年10月建立,该合作研究报告可从世界卫生组织获得,参考号世界卫生组织/BS/2017.2324该制剂的预期用途是标准化治疗性APCC(活化凝血酶原复合物浓缩物)产品中的FXa效力测量。也可以研究参考试剂,以标准化其他治疗产品的FXa测量,或标准化FXa抑制剂的生物活性。任何调查的结果都可能为未来合作研究的性质提供信息,以将15/102确定为世界卫生组织FXa国际标准。在一项合作研究中,根据与凝血因子Xa(75/595)的非-WHO参考物质(FXa的牛制剂)相关的显色分析,确定6.7单位/安瓿[……]

继续阅读

WHO15/102人活化凝血因子X国际标准品FXa Read More »

浅析重金属检测方法-电化学法—阳极溶出伏安法

电化学法—阳极溶出伏安法

检测原理:电化学法是近年来发展较快的一种方法,它以经典极谱法为依托,在此基础上又衍生出示波极谱、阳极溶出伏安法等方法。电化学法的检测限较低,测试灵敏度较高,值得推广应用。如国标中铅的测定方法中的第五法和铬的测定方法的第二法均为示波极谱法。

阳极溶出伏安法是将恒电位电解富集与伏安法测定相结合的一种电化学分析方法。这种方法一次可连续测定多种金属离子,而且灵敏度很高,能测定10-7~10-9mol/L的金属离子。此法所用仪器比较简单,操作方便,是一种很好的痕量分析手段。我国已经颁布了适用于化学试剂中金属杂质测定的阳极溶出伏安法国家标准。

方法:阳极溶出伏安[……]

继续阅读

浅析重金属检测方法-电化学法—阳极溶出伏安法 Read More »

NIBSC15/270 1st WHO International Reference Reagent CD4 T-cells (human)

NIBSC15/270 1st WHO International Reference
Reagent CD4 T-cells (human)

产品详情如下,更多产品详情,请咨询客服,供实验室使用!

Product description
1st WHO International Reference Reagent CD4 T-cells (human)
Product number
15/270 NIBSC15/270
Category

Biotherapeutics Cell Reference Materi[……]

继续阅读

NIBSC15/270 1st WHO International Reference Reagent CD4 T-cells (human) Read More »

NIBSC21/170 1st International Standard 2022 for the in vitro bioactivities of Cetuximab 21/170

NIBSC21/170 1st International Standard 2022 for the in
vitro bioactivities of Cetuximab 21/170

产品详情如下,更多产品详情,请咨询客服,供实验室使用!

Product description
1st International Standard 2022 for the in vitro bioactivities of Cetuximab
Product number
21/170 NIBSC21/170
Category

B[……]

继续阅读

NIBSC21/170 1st International Standard 2022 for the in vitro bioactivities of Cetuximab 21/170 Read More »

NIBSC19/108 Trastuzumab (1st WHO international Standard) 19/108

NIBSC19/108 Trastuzumab (1st WHO international
Standard) 19/108

产品详情如下,更多产品详情,请咨询客服,供实验室使用!

Product description
Trastuzumab (1st WHO international Standard)
Product number
19/108 NIBSC19/108
Category

Biotherapeutics Monoclonal Antibodies

Keywords

Mon[……]

继续阅读

NIBSC19/108 Trastuzumab (1st WHO international Standard) 19/108 Read More »

NIBSC18/210 Bevacizumab (1st WHO International Standard) 18/210

NIBSC18/210 Bevacizumab (1st WHO International
Standard) 18/210

产品详情如下,更多产品详情,请咨询客服,供实验室使用!

Product description
Bevacizumab (1st WHO International Standard)
Product number
18/210 NIBSC18/210
Category

Biotherapeutics Monoclonal Antibodies

Keywords

Bio[……]

继续阅读

NIBSC18/210 Bevacizumab (1st WHO International Standard) 18/210 Read More »

NIBSC14/210 Biological activities of Rituximab WHO 1st International Standard 14/210

NIBSC14/210 Biological activities of
Rituximab WHO 1st International Standard 14/210

产品详情如下,更多产品详情,请咨询客服,供实验室使用!

Product description
Biological activities of Rituximab WHO 1st International Standard
Product number
14/210 NIBSC14/210
Category

Biotherapeutics Mo[……]

继续阅读

NIBSC14/210 Biological activities of Rituximab WHO 1st International Standard 14/210 Read More »

NIBSC17/236 Adalimumab (1st WHO International Standard) 17/236

NIBSC17/236 Adalimumab (1st WHO International
Standard) 17/236

产品详情如下,更多产品详情,请咨询客服,供实验室使用!

Product description
Adalimumab (1st WHO International Standard)
Product number
17/236 NIBSC17/236
Category

Biotherapeutics Monoclonal Antibodies

Keywords

Bioas[……]

继续阅读

NIBSC17/236 Adalimumab (1st WHO International Standard) 17/236 Read More »

NIBSC16/170 WHO International Standard 1st International Standard for Infliximab 16/170

NIBSC16/170 WHO
International Standard 1st International Standard for Infliximab 16/170

产品详情如下,更多产品详情,请咨询客服,供实验室使用!

Product description
WHO International Standard 1st International Standard for Infliximab
Product number
16/170 NIBSC16/170
Category

Biotherapeutics[……]

继续阅读

NIBSC16/170 WHO International Standard 1st International Standard for Infliximab 16/170 Read More »